Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $38,839.92 in Stock

Edgewise Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 854 shares of the business's stock in a transaction on Monday, November 16th. The shares were sold at an average price of $45.48, for a total value of $38,839.92. Following the completion of the sale, the chief marketing officer owned 8,139 shares of the company's stock, valued at $370,161.72. This trade represents a 9.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Edgewise Therapeutics Price Performance

NASDAQ EWTX traded down $0.67 on Wednesday, reaching $41.37. The stock had a trading volume of 866,829 shares, compared to its average volume of 1,290,485. The firm has a fifty day moving average of $41.31 and a two-hundred day moving average of $37.13. Edgewise Therapeutics, Inc. has a 1-year low of $19.76 and a 1-year high of $48.78. The company has a market cap of $4.53 billion, a P/E ratio of 5.05 and a beta of 0.39.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $9.65 earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $10.18. Research analysts predict that Edgewise Therapeutics, Inc. will post 9.11 EPS for the current fiscal year.

Institutional Trading of Edgewise Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new position in Edgewise Therapeutics during the second quarter worth about $268,415,000. Jupiter Topco LLC purchased a new stake in shares of Edgewise Therapeutics during the 2nd quarter valued at approximately $246,945,000. Janus Henderson Group PLC boosted its holdings in Edgewise Therapeutics by 29.5% in the 1st quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company's stock worth $186,289,000 after buying an additional 1,348,706 shares during the period. Bank of America Corp DE purchased a new position in shares of Edgewise Therapeutics in the second quarter valued at $63,312,000. Finally, Marshall Wace LLP grew its position in shares of Edgewise Therapeutics by 20,477.5% in the third quarter. Marshall Wace LLP now owns 1,255,226 shares of the company's stock valued at $50,962,000 after purchasing an additional 1,249,126 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Edgewise Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, October 4th. JPMorgan Chase & Co. raised their price objective on Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, August 20th. HC Wainwright reaffirmed a "buy" rating on shares of Edgewise Therapeutics in a report on Wednesday, October 14th. The Goldman Sachs Group upped their price objective on shares of Edgewise Therapeutics from $32.00 to $36.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Finally, William Blair initiated coverage on shares of Edgewise Therapeutics in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $52.83.

Read Our Latest Report on EWTX

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious muscle disorders. Founded in 2017 and based in Boulder, Colorado, the company researches small-molecule treatments designed to address the underlying biology of muscle and cardiac conditions. Its programs include sevasemten, an investigational therapy for Duchenne and Becker muscular dystrophies, and EDG-7500, an investigational treatment being developed for hypertrophic cardiomyopathy.

Recommended Stories

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Edgewise Therapeutics Right Now?

Before you consider Edgewise Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.

While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines